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Serum paraoxonases (PONs) exhibit a wide range of physiologically important hydrolytic activities, including 
drug metabolism and detoxification of nerve gases. PON1 and PON3 reside on high-density lipoprotein 
(HDL) (the “good cholesterol”), and are involved in the alleviation of atherosclerosis. Members of the 
PON family have been identified not only in mammals and other vertebrates, but also in invertebrates. We 
earlier described the first crystal structure of a PON family member, a directly-evolved variant of PON1, at 
2.2  Å resolution. PON1 is a 6-bladed beta-propeller with a unique active-site lid which is also involved in 
binding to HDL. The 3-D structure, taken together with directed evolution studies, permitted analysis of 
mutations which enhanced the stability, solubility and crystallizability of this PON1 variant. The structure 
permits a detailed description of PON1’s active site and suggests possible mechanisms for its catalytic 
activity on certain substrates.
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Paraoxonase 1 (PON1) is a mammalian enzyme that 
catalyzes the hydrolysis and, thereby, the inactivation 
of various organophosphates (OPs), including the 
nerve agents sarin and soman (1). In recent years it 
has become apparent that PON1 and its two known 
Q and R isoforms also play important roles in drug 
metabolism and in alleviation of atherosclerosis (1, 
2). PON1 is the best studied member of the family of 
mammalian enzymes that includes PON2 and PON3, 
both of which share ∼60 % sequence homology with 
PON1. PON1 and PON3 are associated with the 
cholesterol-carrying particles, high-density lipoprotein 
(HDL) (the “good cholesterol”), whereas PON2 is 
found in many tissues. Polymorphism of the PON1 
gene affects the blood levels of PON1 and its catalytic 
efficacy, and these factors have a major impact on 
the individual’s susceptibility to atherosclerosis, as 
well as to pollutants and insecticides (1). Knockout 
mice, totally lacking PON1, are highly susceptible 
both to atherosclerosis and to OP poisoning (3). 
In vitro assays show that PON1 and PON3 inhibit 
lipid oxidation in low-density lipoprotein (LDL) (“bad 
cholesterol”), thus reducing the levels of oxidized 
lipids that are involved in initiation and progression 
of atherosclerosis (4, 5).
The name paraoxonase is purely historical, since 
the PON family is a hydrolase family with one of 
the broadest specificities known. PON1 efficiently 
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hydrolyzes several synthetic ester substrates, whilst 
PON2 and PON3 exhibit high lactonase activity. 
However, the paraoxonase activity of PON1 is rather 
weak, and both PON2 and PON3 exhibit almost no 
such activity (1). A variety of physiological roles have 
been proposed for PONs, including phospholipase 
A2 action in the hydrolysis of platelet-activating factor 
(6) as well as of oxidized lipids (7), and hydrolysis and 
inactivation of homocysteine thiolactone - a known 
risk factor for atherosclerotic vascular disease (8). The 
anti-atherosclerotic activity of the PONs is intimately 
linked to their localization on HDL particles. HDL has 
two key roles: mediation of cholesterol efflux, e.g. from 
macrophage foam cells in atherosclerotic lesions, 
and limitation of lipid oxidation in LDL (9). PONs 
have been implicated in both (2, 10, 11). It has been 
suggested that the hydrophobic N-terminus of PON1 
mediates its anchoring to HDL (12), but the precise 
mode of binding of PONs to HDL, as well as of other 
HDL-associated proteins, is still unknown.
We recently described the directed evolution 
of PON1 and PON3 variants that are expressed 
in a soluble and active form in E. coli, and exhibit 
enzymatic properties virtually identical to those 
reported for PONs purified from sera (13). We also 
reported the crystal structure of a recombinant PON1 
variant derived from rabbit PON1 that is very similar 
in sequence to human PON1 (14). By combining 
directed evolution, site-directed mutagenesis and 
kinetic studies, we analyze the factors which contribute 
to the variant’s enhanced stability and crystallizability, 
and provide a description of the overall architecture of 
PON1 and of some of its catalytic mechanisms.
METHODS
Structure determination, directed evolution and 
enzyme kinetics have been described by Harel et al. 
(14). Coordinates and structure factors were deposited 
in the PDB with entry code 1v04.
RESULTS
Crystallization and structure determination
Previous attempts to determine the structure of 
PON1 relied on limited amounts of serum-purified 
proteins, and led to the crystallization of a protein 
that was  co-purified with it (15). Human PON1 
is rather unstable, and tends to aggregate in the 
absence of detergents (16). Nor is it amenable 
to functional expression in bacteria or yeast, and 
thus to mutagenesis, library selection, and protein 
engineering. These factors led us to directly evolve 
PONs for bacterial expression and increased solubility 
(13). Family shuffling of four PON1 genes (human, 
rabbit, mouse and rat), followed by screening for 
esterolytic activity, led to recombinant PON1 variants 
(rePON1s) that are expressed well in E. coli. These 
variants diverged from the wild-type (wt) rabbit PON1 
by 14-32 amino acids contributed by the other 
three PON1 genes. The rePON1 variants exhibited 
enzymatic properties essentially identical to those of 
the wt PON1 (13), and similar biological activities in 
inhibiting LDL oxidation and mediating cholesterol 
efflux from macrophages (17, 18). Variants from 
the first round of evolution displayed a tendency 
to aggregate, and none could be crystallized. The 
second-generation variants, obtained by shuffling of 
the first-generation variants and screening for highest 
expression levels, did not aggregate, and one (G2E6) 
yielded stable well-diffracting crystals.
RePON1-G2E6 exhibits 91 % homology to the wt 
rabbit PON1 (Figure 1), with the majority of variations 
deriving from human, mouse, or rat wt PON1. Rabbit 
Figure 1 Sequence alignment of rabbit PON1 with six variants for which 
crystallization trials were performed. G2E6 is the variant which 
produced the crystals whose X-ray structure was solved. For 
each sequence, only the residues that differ from the sequence 
of rabbit PON1 are shown. Mutations unique to variant G2E6 
are highlighted in yellow.
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and human PON1s are also highly homologous 
in sequence (86 %) and function (19). Sequence 
variations between rePON1-G2E6 and rabbit and 
human PON1 are in regions that do not affect their 
active sites.
The refined 2.2 Å crystal structure of rePON1 
(R-factor 18.5 %; R-free 21.7 %) contains one 
molecule per asymmetric unit. It was solved by single 
isomorphous replacement anomalous scattering 
(SIRAS) from data collected on crystals of the native 
protein and of the selenomethionine (SeMet) protein 
at 2.6 Å resolution. The structure shows all residues 
except N-terminal residues 1-15 and a surface loop 
72-79. Two calcium atoms, a phosphate ion, and 115 
water molecules are also seen.
Rabbit PON1 vs. rePON1 G2E6
Figure 2 shows G2E6, whose X-ray structure shows 
31 of the 32 residues (the mutation in residue #12 
is in the N-terminus region which has no electron 
density) that are mutated relative to the rabbit PON1 
sequence. Twenty-two of these differences are on the 
surface of the molecule, and nine are in the core. Nine 
of the inner core mutations are from one hydrophobic 
residue to another. It has been suggested that the 
enhanced stability of G2E6 is due to three mutated 
residues which are common to all the variants for 
which crystallization experiments were performed (see 
Figure 2). These are Met341Leu and Val343Ile, both 
hydrophobic core residues that pack against each 
other, and the neighbouring Ala320Val. Roodveldt et 
al. (20) have suggested that these mutations increase 
the stability of the calcium-free apo-form of PON1.
Detergent-solubilized PON1 forms dimers and 
higher oligomers (16), but there is only one molecule 
per asymmetric unit of the crystal, and very few 
contacts between symmetry-related molecules. It 
is possible that crystallization favours a monomeric 
form.
The catalytic mechanism
The upper of the two calcium ions seen in the crystal 
structure, Ca-1, lies at the bottom of the active-site 
cavity, together with a phosphate ion coming from the 
mother liquor (14). One of this phosphate’s oxygens 
is only 2.2 Å from Ca-1. This phosphate ion may be 
bound in a mode similar to the intermediates in the 
hydrolytic reactions catalyzed by PON, with the oxygen 
adjacent to Ca-1 mimicking the oxyanionic moiety 
of those intermediates stabilized by the positively-
charged calcium ion. This type of “oxyanion hole” 
is seen in secreted phospholipase A2 (21), and has 
also been suggested for diisopropylfluorophosphatase 
(22), whose overall structure closely resembles that 
of PON1. Two other phosphate oxygens may be 
mimicking the attacking hydroxyl ion and the oxygen 
of the alkoxy or phenoxy leaving groups of ester and 
lactone substrates.
To help elucidate PON1’s mechanism, we 
determined its catalytic pH-rate profile. The pH- 
dependence observed may be ascribed to a histidine 
imidazole involved in a base-catalyzed, rate-determining 
step. In hydrolytic enzymes, histidine often serves as 
a base, deprotonating a water molecule, and thus 
generating the attacking hydroxide ion that produces 
hydrolysis.
We identified a His-His dyad near both Ca-1 and the 
phosphate ion (Figure 3). We hypothesize that His115 
(the closer nitrogen of which is only 4.1 Å from Ca-1) 
acts as a general base to deprotonate a single water 
molecule, thus generating the attacking hydroxide, 
while His134 acts in a proton shuttle mechanism to 
increase His115’s basicity. Interestingly, His115 adopts 
Figure 2 Cartoon image of the 6-bladed beta-propeller structure of 
the recombinant PON1 variant G6E2. The variant’s mutated 
residues, relative to wild type rabbit PON1, are shown as 
magenta and cyan balls, the cyan balls indicating unique 
mutations in G2E6 not shared by the 5 other variants of PON1 
that failed to crystallize. The two calcium ions are shown as 
green balls, and the phosphate ion as a red stick model. Two 
of the blades, 3 (green) and 4 (yellow), are mutation-free.
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distorted dihedral angles - a phenomenon observed 
in catalytic residues of many enzymes. In support of 
the postulated mechanism we investigated His115Gln, 
His115Ala, and His115Trp mutations, all of which 
produce a dramatic decrease in both arylesterase 
and lactonase activity of PON1, and the His134Gln 
mutation, that resulted in a milder, yet significant, 
decrease. Interestingly, the paraoxonase activity of 
the PON1 variant was not affected by any of these 
His mutations (18).
DISCUSSION
This study complements earlier examples of 
the application of directed evolution for protein 
crystallization (23). Directed evolution was also 
applied to identify PON1’s active site, and provided 
key insights as to how the substrate selectivity of the 
PON family members evolved in nature. Two thirds 
of the mutations in the G62E mutant are found on 
the surface of the molecule. The alignment of all the 
PON1 variants that were subjected to crystallization 
trials (Figure 1) show that the crystallized variant 
G2E6, which was crystallized successfully, has about 
twice as many mutations as those which could 
not be crystallized. Thus, it bears 32 mutations vs. 
13-19 mutations for the 3 variants which did not 
crystallize. Ten of these mutations are unique to the 
G2E6 variant. They are all located on the surface of 
PON1, yet they do not make contacts with symmetry-
related molecules in the crystal. This work shows the 
advantage of directed evolution in generating a range 
of variants that are very similar, of which only some 
might readily form crystals. The mutations in the G2E6 
variant are spread throughout most of the molecule 
except for two blades of the six-bladed beta-propeller, 
blades 3 and 4, neither of which bears a mutation (see 
Fig. 2). Detergent-solubilized PON1 forms dimers and 
higher oligomers (16), although the crystal structure 
contains only one monomer in the asymmetric unit. It 
is possible that the mutation-free surface is the site of 
dimerization of the PON1, being in this respect similar 
to the highly soluble bacterial phosphotriesterase 
variants which contain only 3 point mutations, which 
are all distal from the dimer surface (24); in this latter 
case the dimer surface is also mutation-free.
The crystal structure unravels both the overall fold 
of the PON family and the details of PON1’s structure. 
It permits postulation of the catalytic mechanism of 
the esterase and lactonase functions of PONs. The 
mutagenesis data (18) indicate that these two activities 
of PON1 are catalyzed by a His115-His134 dyad, while 
the paraoxonase activity is not affected by the dyad 
mutations and, hence, must be catalyzed by different 
residues.
The directed evolution results demonstrate the 
remarkable evolvability of this enzyme family, and its 
Figure 3 The postulated catalytic site and mechanism of PON1. A) The catalytic site: the upper calcium atom (Ca-1), the phosphate ion at the 
bottom of the active site, and the postulated His-dyad; B) Schematic representation of the proposed mechanism of action of PON1 on ester 
substrates such as phenyl and 2-naphthylacetate. The first step involves deprotonation of a water molecule by the His dyad to generate
a hydroxide anion which attacks the ester carbonyl, producing an oxyanionic tetrahedral intermediate. This intermediate breaks down
(second step) to an acetate ion and either phenol or 2-naphthol.
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impact on obtaining active, stable, and soluble protein 
variants which are amenable to crystallization and to 
subsequent 3-D structure determination.
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Sa`etak
3-D STRUKTURA SERUMSKE PARAOKSONAZE 1 OBJA[NJAVA NJEZNU AKTIVNOST, STABILNOST, 
TOPLJIVOST I KRISTALIZACIJU
Serumske paraoksonaze (PONs) imaju {iroki raspon fiziolo{ki va`nih hidroliti~kih aktivnosti uklju~uju}i 
metabolizam lijekova i detoksikaciju nervnih plinova. PON1 i PON3 smje{tene su na lipoproteinima 
visoke gusto}e (engl. high-density lipoprotein; HDL - “dobri kolesterol”) i uklju~ene su u ubla`avanje 
ateroskleroze. ^lanovi skupine PON identificirani su ne samo u sisavaca i drugih kralje`njaka ve} i kod 
beskralje{njaka. Prije smo opisali prvu kristalnu strukturu ~lana PON skupine, direktno razra|enu varijantu 
PON1 pri rezoluciji 2,2 Å. PON1 je beta-propeler sa {est lopatica s jedinstvenim poklopcem aktivnog 
mjesta, koji je tako|er uklju~en u vezanje na HDL. 3-D struktura, gledana zajedno s direktnim razvojnim 
istra`ivanjima, omogu}ila je analizu mutacija koje pove}avaju stabilnost, topljivost i kristalizaciju te PON1 
varijante. Struktura dopu{ta detaljan opis aktivnog mjesta PON1 i sugerira mogu}e mehanizme za njezinu 
kataliti~ku aktivnost prema odre|enim supstratima.
KLJU^NE RIJE^I: kataliti~ki mehanizam, usmjerena evolucija, varijante koje tvore kristale
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